Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12718246 | 0.87 | BCHE (0.36) | NCF1GNAO1GNAI3GNAI1PRMT6 | |
| SCHEMBL13906105 | 0.83 | GNAO1 (0.45) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL1628330 | 0.82 | ALOX15 (0.52) | NCF1GNAO1GNAI3GNAI1PRMT6 | |
| SCHEMBL23828683 | 0.81 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL10076885 | 0.81 | DRD2 (0.47) | GNAO1GNAI3GNAI1KCNH2 | |
| Hydrochloric Acid SCHEMBL598320 | 0.80 | GNAO1 (0.54) | NCF1GNAO1GNAI3GNAI1PRMT6 | |
| SCHEMBL12561560 | 0.79 | GNAO1 (0.50) | GNAO1GNAI3GNAI1KCNH2 | |
| Hydrochloric Acid SCHEMBL30331039 | 0.79 | DRD2 (0.46) | GNAO1GNAI3GNAI1 | |
| Fluoride SCHEMBL29252261 | 0.79 | DRD2 (0.46) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL2280533 | 0.79 | NCF1 (0.56) | NCF1GNAO1GNAI3GNAI1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | NCF1 1447/4885GNAO1 1775/4885GNAI3 624/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | NCF1 1371/4885GNAO1 1373/4885GNAI3 3092/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | NCF1 1466/4885GNAO1 828/4885GNAI3 787/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | NCF1 1061/4885GNAO1 2674/4885GNAI3 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.